Eli Lilly Soars on Blowout Q4 as Weight-Loss Drugs Power Upbeat 2026 Outlook

A guidance boost above Wall Street, fueled by surging weight-loss sales, sent shares sharply higher.

Overview

Adjusted Q4 earnings reached $7.54 per share versus $6.91 expected as revenue rose 43% to $19.3 billion, topping the $17.9 billion consensus.
Weight-loss brands led growth with Mounjaro revenue at $7.4 billion and Zepbound at $4.3 billion on strong volume.
Lilly projected 2026 revenue of $80 billion to $83 billion and EPS of $33.50 to $35, both above Street forecasts.
Shares jumped 8.3% premarket and finished up 10.33% on Wednesday following the results and outlook.
The company highlighted expanded U.S. access with cash pricing for Zepbound and recent regulatory filings for the oral obesity candidate orforglipron in the U.S., Japan, and the EU.